Atai Life Sciences N.V. (ATAI) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Net Income Growth ATAI has had growing net income for the last 2 years
Price to Book (PBV) Ratio Overvalued price-to-book. ATAI stock price is overvalued by more than 1x the price-to-book value.
Debt-Equity Ratio (DER) ATAI equity is higher than it's debt.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth ATAI has never had growing revenue.
Net Income ATAI never has positive net income for 2 years.
Dividend Yield ATAI has low dividend yield (0%).
Return of Assets ATAI has low return of asset (-57.28%).
Return of Equity ATAI has low return of equity (-59.29%).
Revenue ATAI never has positive revenue for 2 years.
Return of Invested Capital ATAI has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-64,374,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Management

About Atai Life Sciences N.V.

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Additional Information

Company name

Atai Life Sciences N.V.

Symbol

NASDAQ:ATAI

Exchange

NASDAQ Global Market

Industry

Biotechnology

Sector

Healthcare

Address

Krausenstrasse 9-10
Berlin

DE
10117

Website

https://www.atai.life